[Resurgence of Mycoplasma pneumoniae: a new epidemic ?]
| Autor: | Bouras K; Service de médecine interne, Hôpital de La Tour, 1217 Meyrin/Genève., Schrenzel J; Laboratoires de bactériologie et génomique, Hôpitaux universitaires de Genève et Université de Genève, 1211 Genève 4.; Service des maladies infectieuses, Département de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14., Fischer A; Laboratoires de bactériologie et génomique, Hôpitaux universitaires de Genève et Université de Genève, 1211 Genève 4., Liassine N; Dianalabs, 1205 Genève., Rosselin M; Dianalabs, 1205 Genève., Jost G; Dianalabs, 1205 Genève., Adler D; Unité cardiopulmonaire, Service de pneumologie, Soins intensifs, Hôpital de La Tour, 1217 Meyrin/Genève., Younossian AB; Unité cardiopulmonaire, Service de pneumologie, Soins intensifs, Hôpital de La Tour, 1217 Meyrin/Genève. |
|---|---|
| Jazyk: | francouzština |
| Zdroj: | Revue medicale suisse [Rev Med Suisse] 2024 Nov 13; Vol. 20 (895), pp. 2093-2098. |
| DOI: | 10.53738/REVMED.2024.20.895.2093 |
| Abstrakt: | Mycoplasma pneumoniae pneumonia occurs periodically in an endemic-epidemic pattern. The incidence of this disease has fallen drastically as a result of the health measures imposed for the COVID-19 pandemic. In Switzerland, as elsewhere in the world, a new epidemic has been affecting pediatrics and adult populations since September 2023. Transmitted by aerosols and requiring close contact, this bacterium causes respiratory infections of varying severity, as well as a variety of extra-pulmonary manifestations. Microbiological diagnosis is based on PCR of respiratory samples. Despite a very high rate of macrolide resistance in Asia, the resistance rate remains low in Europe. Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|